Compare iShares MSCI Australia ETF (EWA) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Cassava Sciences Inc — how do they compare? iShares MSCI Australia ETF trades at $28.59 (market cap $1.17B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: iShares MSCI Australia ETF is far larger — about 29.7× Cassava Sciences Inc's market cap, and iShares MSCI Australia ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Cassava Sciences Inc for 37 Days on average.
| EWA | FLNA | |
|---|---|---|
Market Cap | $1.17B | $39.40M |
Volume | 2,121,231 | 759,018 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $4.64 |
52-Week Low | $24.95 | $0.68 |
Typical Hold Time | 61 Days | 37 Days |
Enterprise Value | — | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.56, up 1.17% today, but technical indicators are bearish with all moving averages signaling sell. The ETF provides exposure to Australian equities, heavily weighted toward commodities and financials. Recent news highlights institutional selling by Squarepoint Ops LLC and broader Australian market pressures from inflation concerns due to rising oil prices.
The outlook remains cautious amid bearish technicals and macroeconomic headwinds, though some analysts see upside potential from commodity strength. Risks include persistent inflation, tight monetary policy, and reliance on raw material exports. Investors should weigh technical weakness against long-term commodity-driven growth prospects.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
